MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
Recruiting
Observational Study
Multiple Sclerosis (MS)
Cerebral Small Vessel Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 50 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Oslo University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS). In older individuals with MS, white matter changes seen on MRI may be related to MS or to other types of white matter changes, most commonly age-related changes or chronic small ve…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria Multiple Sclerosis (MS) cohort (AgeMS):
* Age 50-70 years
* Clinically confirmed diagnosis of multiple sclerosis
* Participation in the AgeMS study at Oslo University Hospital
Inclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort:
* Age 50-80 years
* Radiologic…
Contacts